Leukogene Therapeutics, Inc. (LTI) is a start-up oncology drug discovery and development company out of the Medical University of South Carolina in Charleston, South Carolina. LTI is currently in the late stages of preclinical development for a new class of protein disulfide isomerase (PDI) inhibitor for the treatment of several solid and hematological cancers. LTI's lead molecules attack cancer through this novel mechanism, and have the added benefit of enhancing the effects of two other classes of targeted cancer therapy.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):